The world's largest retailer and the nation's largest private employer kicked off the on-the-spot surprise promotions at ceremonies Tuesday in its Secaucus, N.J., store and about 15 other markets including Atlanta and Denver. It's dispatching top executives to stores nationwide for similar events for the rest of its fiscal year, which ends in late January.
The mostly hourly workers will be promoted to different jobs ��some to store management positions ��and will receive higher pay and increased responsibility.
"It's good a time as any to tell our story," said Bill Simon, president and CEO of Wal-Mart's U.S. namesake division. He was at the Secaucus store Tuesday at a ceremony to promote six to eight workers.
Top 5 Integrated Utility Companies To Own For 2015: Henry Schein Inc. (HSIC)
Henry Schein, Inc. distributes healthcare products and services primarily to office-based healthcare practitioners. It operates in two segments, Healthcare Distribution and Technology. The Healthcare Distribution segment offers consumable dental products, dental laboratory products, and small equipment, including X-ray products, infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, and abrasives; and large dental equipment comprising dental chairs, delivery units and lights, X-ray equipment, equipment repair, and high-tech equipment. It also provides medical products, including branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, and vitamins; and animal health products, such as branded and generic pharmaceuticals, surgical and consumable products and services, and equipment. The Technology segment offers softwar e and related products, and value-added products that primarily include practice management software systems for dental and medical practitioners, and animal health clinics. Its services also consist of financial services and continuing education services for practitioners. Henry Schein, Inc. primarily serves dental practitioners and laboratories, physician practices, and animal health clinics, as well as government and other institutions. It operates in the United States, Australia, Austria, Belgium, Canada, China, the Czech Republic, France, Germany, Hong Kong, Ireland, Israel, Italy, Luxembourg, the Netherlands, New Zealand, Portugal, Slovakia, Spain, Switzerland, and the United Kingdom. The company was founded in 1932 and is headquartered in Melville, New York.
Advisors' Opinion:- [By John Bonnanzio]
The fund�� top holdings are Telsa, Henry Schein (HSIC), United Rentals (URI), Gartner (IT) and Kansas City Southern (KSU).
The fund also has some exposure to pricey biotech. Even so, this is hardly a shoot-the-lights-out growth fund as volatility is below all his mid-cap peers. To that end, this trade actually tempers risk while increasing growth exposure.
Top 5 Prefered Stocks To Buy Right Now: MiMedx Group Inc (MDXG)
MiMedx Group, Inc. (MiMedx), incorporated on February 28, 2008, is an integrated developer, manufacturer and marketer of regenerative biomaterial products processed from human amniotic membrane. The Company�� biomaterial platform technologies include the device technologies HydroFix and CollaFix, and tissue technologies, AmnioFix and EpiFix. Its tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through the Company�� donor program, mothers delivering full-term caesarian births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce a manipulated implant for homologous use. MiMedx is the supplier of amniotic tissue, having supplied over 100,000 implants to distributors and other equipment manufacturers (OEMs) for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
The Company has three platform technologies. Its largest addressable market is in chronic wound care consisting of diabetic, venous and pressure ulcers. On January 5, 2011, the Company acquired all of the outstanding equity interests in Surgical Biologics, LLC. Located in Kennesaw, Georgia, Surgical Biologics develops allografts and other products processed from human amniotic membrane that can be used for a range of medical applications, including ocular surface repair, gum repair, wound care, nerve and tendon repair, spine repair, burn treatment, and many other types of procedures that require the repair of a patient�� integumental (native) tissue. Surgical Biologics has developed a specialized process for the processing of amniotic membrane to produce a manipulated allograft for homologous use.
AmnioFix and EpiFix
MiMedx is the supplier of allografts processed from amniotic tissue, having supplied over 70,000 allografts to date for application in the Ophthalm! ic, Orthopedic, Dental, Spinal and Wound Care segments of healthcare. Its amnion products, AmnioFix and EpiFix, are processed from human tissue. The AmnioFix and EpiFix allografts can be used for a range of procedures, including ocular surface repair, gingival recession repair, wound care, burns, and many other types of procedures for the repair of a patient�� integumental (native) tissue. Its AmnioFix technology also is used as a graft to reduce the amount of scar tissue formation, provide a local anti-inflammatory and help with the soft tissue healing of the area. EpiFix offers a range of wound healing and wound care options. Much of the clinical usage of EpiFix has been for wound care patients suffering from diabetic ulcers, pressure ulcers, vein circulation ulcers, or artery circulation ulcers.
CollaFix
The Company�� CollaFix technology combines a means of creating fibers from soluble collagen and a specialized cross-linking process. MiMedx utilizes two separate cross-linking technologies for various applications. Initial laboratory and animal testing shows that the cross-linked collagen fibers produce a biocompatible, and durable construct that can be transformed into surgical meshes intended to treat a number of orthopedic soft-tissue trauma and disease disorders.
HydroFix
The Company licenses rights to a polyvinyl alcohol (PVA) polymer, which is a water-based biomaterial that can be manufactured with a range of mechanical properties, including those that appear to mimic closely the mechanical and physical properties of natural, healthy human tissue. This hydrogel has been used in other orthopedic and general surgery device applications, and it has demonstrated biocompatibility and durability inside the human body. It has a similar version of the product for the European market called HydroFix Spine Shield. The device is classified as a post-surgical adhesion inhibiting barrier and is used in specific spine surgeries. In December the original! HydroFix! Spine Shield (for Anterior use Class IIb in Europe) was renamed to be HydroFix Anterior Shield.
The Company competes with W.L. Gore & Associates, Inc. and Stryker.
Advisors' Opinion:- [By Rich Smith]
MiMedx Group (NASDAQ: MDXG ) ,�announced�Monday that results from a randomized controlled trial for its EpiFix wound-care allograft have been published in the International Wound Journal.�
The clinical trial included patients with diabetic foot ulcers of at least four weeks' duration without infection, having adequate blood supply. Patients were broken into two groups, one receiving standard care alone, the other standard care plus EpiFix. After four and six weeks of treatment, the overall healing rate of patients treated with EpiFix was 77% and 92%, respectively, whereas standard care healed 0% and 8% of the wounds, respectively. The rate of healing with EpiFix exceeded that of standard treatment as well.
According to the World Health Organization, diabetes will affect 366 million people worldwide -- up from 171 million in 2000.�Approximately 25% of diabetics will develop a chronic non-healing ulcer over their lifetime.�Diabetic foot ulcers�occur in 15% of all patients with diabetes and precede 84% of all lower leg amputations.
EpiFix makes use of dehydrated human amniotic membrane to heal these ulcers. At room�temperature, EpiFix can have a shelf life of five years and retains the properties of the natural membrane.�Although there are similar, competing products on the market, the superior performance of�EpiFix compared with rival products (not yet proven by published studies) could help to make the company a market leader in the treatment of diabetic foot ulcers. - [By Garrett Cook]
MiMedx Group (NASDAQ: MDXG) shares were also up, gaining 12.10 percent to $7.04 after the company reported Q2 earnings of $0.00 per share on revenue of $25.60 million and raised its FY14 sales outlook.
- [By Sean Williams]
What: Shares of MiMedx Group (NASDAQ: MDXG ) , a manufacturer of patented regenerative biomaterial products (in essence, products designed to treat inflammation and help wounds heal), were eviscerated, falling as much as 70% at one point before recovering half of its losses after it announced the receipt of an untitled letter from the Food and Drug Administration alleging it does not possess the proper licensing to manufacture certain products.
- [By Bryan Murphy]
It may not be as big as NuVasive, Inc. (NASDAQ:NUVA), and it might not be as sexy as MiMedx Group Inc. (NASDAQ:MDXG). But, Bacterin International Holdings Inc. (NYSEMKT:BONE) offers something to investors that MDXG and NUVA don't - can't - right now... a distinct opportunity for a lot of upside in a short amount of time.
Top 5 Prefered Stocks To Buy Right Now: Mediobanca Banca di Credito Finanziario SpA (MB)
Mediobanca Banca di Credito Finanziario SpA is an Italy-based bank. Together with its subsidiaries, the Company's activities are divided into three main segments: Corporate and Investment Banking (CIB), Principal Investing (PI) and Retail and Private Banking (RPB). In the CIB segment, the Bank is engaged in the investment banking activities, leasing services and trading investments. The PI segment comprises the Bank�� shareholdings in companies involved in the insurance sector, multimedia publishing activities and telecommunication services, as well as stakes acquired as part of merchant banking activity and investments in private equity funds. The RPB consists of financial products and services provided to retail customers, including consumer credit products, mortgages, deposit accounts, private banking and fiduciary activities. In September 2013, the Company launched the sale of its investment in Telco. Advisors' Opinion:- [By Bloomberg]
Mattel (MAT), the world's largest toymaker, agreed to buy Mega Brands (MB) for $460 million, acquiring the biggest challenger to Lego A/S in the construction-toy market. Mattel is offering C$17.75 ($16) a share, according to a statement today, a 36 percent premium over yesterday's closing price. The board of Montreal-based Mega Brands unanimously approved the transaction, and investors holding 39 percent of the stock, including Chief Executive Officer Marc Bertrand and Fairfax Financial Holdings (FFH), agreed to the deal. The purchase of Mega Brands, the world's second-largest maker of snap-together blocks, will fill a product hole for Mattel. It doesn't have its own construction line, locking it out of a $4 billion market in the U.S. and Europe. The category also is a bright spot in a toy industry that has seen growth stall in the U.S. Mattel considered starting its own construction line, then opted instead to buy Mega Brands because it would be faster and less risky, Mattel CEO Bryan G. Stockton said on a call with reporters. Mattel got its first taste of construction in 2012 when it debuted blocks for its Barbie brand through a licensing deal with Mega Brands. Mattel realized that replicating this kind of expertise would take years, Stockton said. 'About Growth' "This acquisition is all about growth," Stockton said. "We see an opportunity to expand our brands in this category across boys, girls and preschool." Mattel shares rose 0.8 percent to $37.44 at 10:34 a.m. in New York. They had declined 9 percent over the past year through yesterday. Shares of Montreal-based Mega Brands surged 36 percent to C$17.73 today in Toronto. Mattel is coming off a lackluster holiday season, with sales sinking 6.3 percent -- the biggest quarterly drop since 2009. The El Segundo, California-based toymaker has looked to acquisitions to boost sales in the past. In February of 2012, it paid $680 million to buy HIT Entertainment, owner of Thomas the Tank Engine. It also acq
Top 5 Prefered Stocks To Buy Right Now: Value Line Inc (VALU)
Value Line, Inc., incorporated on October 29, 1982, is engaged in producing investment periodicals and related publications and making available copyright data, including certain Ranking System and other information, to third parties under written agreements for use in third-party managed and marketed investment products. The Company operates in two segments: investment periodicals and related publications. During the fiscal year ended March 31, 2013 (fiscal 2013), the Company�� Wholly-owned operating subsidiaries include Value Line Publishing LLC, Vanderbilt Advertising Agency, Compupower Corporation (CPWR) and Value Line Distribution Center (VLDC). The Company markets under brands including Value Line, the Value Line Logo, The Value Line Investment Survey and The Most Trusted Name in Investment Research.
Investment Related Periodicals and Publications
The investment periodicals and related publications offered by Value Line Publishing LLC (VLP) covers a spectrum of investments, including stocks, mutual funds, options and convertible securities. The services generally fall into four categories include Comprehensive reference periodical publications; Targeted, niche periodical newsletters, and Current and historical financial databases. The services (The Value Line Investment Survey, The Value Line Investment Survey - Small and Mid-Cap, The Value Line 600, and The Value Line Fund Advisor Plus) provide both statistical and text coverage of a number of investment securities, with a focus placed on Value Line's research, analysis and statistical ranks. The Value Line Investment Survey is the Company's premier service, published each week and covering approximately 1,700 stocks.
The newsletters (The Value Line Special Situations Service, The Value Line Fund Advisor, The Value Line Convertibles Survey and The Value Line Options Survey) provide information on securities. The Company offers online versions of its products at the Company's Website, www.valueline.com. T! he Value Line Investment Survey is an investment periodical research product providing both timely articles on economic, financial and investment matters and analysis and ranks for equity securities. The Value Line Investment Survey is an investment periodical research product providing both timely articles on economic, financial and investment matters and analysis and ranks for equity securities. The Value Line Investment Survey - Small and Mid-Cap is an investment research product that provides short descriptions of and data for approximately 1,800 small and medium-capitalization stocks.
Value Line Investment Analyzer is a menu-driven software program with filtering, ranking, reporting and graphing capabilities utilizing over 350 data fields for range of industries and indices and for the approximately 1,700 stocks covered in VLP's publication, The Value Line Investment Survey. Value Line Investment Analyzer allows subscribers to apply more than 60 charting and graphing variables for comparative research. Value Line Mutual Fund Survey for Windows is a monthly CD-ROM or Internet product with weekly Internet updates. The program features powerful sorting and filtering analysis tools. It includes features, such as style attribution analysis, a portfolio stress tester, portfolio rebalancing, correlation of fund returns and hypothetical assets. For the Company's institutional customers, Value Line offers both current and historical data for equities, mutual funds, exchange traded funds (ETFs), and convertibles.
Value Line's Fundamental DataFile I contains fundamental data (both current and historical) on approximately 6,400 publicly traded companies that follow United States generally accepted accounting principles (GAAP). Estimates and Projections DataFile offering contains the estimates from Value Line analysts on approximately 1,700 companies. Data includes earnings, sales, cash flow, book value, margin, and other popular fields. Projections are for the future one year, three ! year and ! five year periods. The Value Line Mutual Fund DataFile, covers more than 20,000 mutual funds with up to 20 years of historical data with more than 200 data fields. The Mutual Fund DataFile provides monthly pricing, basic fund information, weekly performance data, sector weights, and many other popular mutual fund data fields. The Value Line Research Center provides on-line access to select Company investment research products covering stocks, mutual funds, options and convertible securities, as well as special situation stocks.
Copyright Data Fees Programs
The Company has copyright data, which include certain ranking system information and other information used in third party products, such as unit investment trusts, variable annuities, managed accounts and exchange traded funds, which it distributes under copyright data agreements. The Company�� primary copyright data products have been structured as unit investment trusts, ETFs, annuity products and other types of managed products.
Investment Management Services
The Company through its wholly-owned subsidiary ESI, was the distributor for the Value Line Funds. State Street Bank is the custodian of the assets of the Value Line Funds and provides them with fund accounting and administrative services. Shareholder services for the Value Line Funds are provided by Boston Financial Data Services, an affiliate of State Street Bank.
Advisors' Opinion:- [By Geoff Gannon]
If a company has an at risk business, it can allocate capital to other areas. Many successful companies no longer engage in the business they started in. If American Express (AXP) stayed in its original business, it wouldn't be around today. The same is true of IBM, MMM, and BRK.B. Some companies choose to pay large dividends or buy back stock while the business is failing rather than allocating capital into a different industry. Let's look at Value Line (VALU). Over the last 10 years, Value Line has paid out about 85% of the company's current market cap. It's a dying business. It had a decision to make. It could allocate capital to new areas inside the corporation, it could pay dividends, or it could buyback stock. It chose to pay dividends.
- [By Geoff Gannon] be cheap enough. It was an issue of Warren Buffett being confident enough to invest in IBM.
By the way, let�� look at IBM�� past record:
10-Year Average Return on Assets: 10.3%
10-Year Annual Sales Growth: 2.8%
10-Year Annual Asset Growth: 1.9%
As you can see, IBM isn�� much of a growth company. But that doesn�� mean the shares can�� be growth shares. IBM has improved margins and bought back stock. That has led to a 20% annual increase in earnings per share compared to just a 3% annual increase in total revenue.
So can we answer the question of why Warren Buffett is interested in companies like IBM and Norfolk Southern (NSC) rather than Hewlett-Packard and Value Line?
Well, Value Line is obviously too small an investment for Buffett. But we��e using it as a stand in for all the publishers Buffett once loved but now shuns.
Buffett is a return on investment investor. He isn�� exactly a growth investor or a value investor ��if by growth we mean total revenue growth and if by value we mean the company�� value as of today.
Buffett wants to compound his money at the fastest rate possible. So he looks at how much of the company�� sales, assets, etc. he is getting. Basically, he looks at a price ratio. And then he looks into the company�� return on its own sales, assets, etc. When you take those two numbers together you get something very close to a rate of return.
The last part you need to consider is the change in assets versus the change in sales (and earnings). Does the company need to grow assets faster than earnings?
Or ��like See�� Candy ��can it grow sales a little faster than assets?
Let�� take a look at Norfolk Southern as a good example of the kind of railroad Buffett would own ��if he didn�� own all of Burlington Northern.
Norfolk Southern
10-Year Average Return on Assets: 4.9%
10-Year Annual Sales Growth: 6.0%
10-Year Annual Asset Gr
No comments:
Post a Comment